In murine models of pancreatic cancer, treatment with JAK-STAT inhibitor Ruxolitinib suppressed tumor growth, decreased PD-L1 expression, and enhanced Cytotoxic T Lymphocyte activation, with the lowest tumor growth observed with combined Ruxolitinb and anti-PD-1 mAb immunotherapy [110]. This evidence concerns the gene CD274 and neoplasm.